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Abstract 
The  clinical  application  of  cellular  based
therapies with ex vivo cultivation for the treat-
ment of diseases of the musculoskeletal sys-
tem has until now been limited. In particular,
the  advanced  laboratory  and  technical  effort
necessary,  regulatory  issues  as  well  as  high
costs are major obstacles. On the other hand,
newly developed cell therapy systems permit
intra-operative enrichment and application of
mesenchymal and progenitor stem cells from
bone marrow aspirate concentrate (BMAC) in
one single operative session. The objective of
the present clinical surveillance study was to
evaluate new bone formation after the applica-
tion of BMAC as well as to record any possible
therapy-specific complications 
For  this  purpose,  the  clinical-radiological
progress of a total of 101 patients with various
bone  healing  disturbances  was  documented
(surveillance  study).  The  study  included  37
necrosis of the head of the femur, 32 avascular
necroses/bone marrow edema of other local-
ization, 12 non-unions, 20 other defects. The
application  of  BMAC  was  performed  in  the
presence of osteonecrosis via a local injection
as part of a core decompression (n=72) or by
the local adsorption of intra-operative cellular
bone substitution material (scaffold) incubat-
ed with BMAC during osteosynthesis (n=17)
or in further surgery (n=12). 
After  an  average  of  14  months  (2-24
months), the patients were re-examined clini-
cally  and  radiologically  and  interviewed.
Further surgery was necessary in 2 patients
within the follow-up period. These were due to
a progression of a collapsed head of the femur
with initial necrosis in ARCO Stage III, as well
as inadequate new bone formation with sec-
ondary loss of correction after periprosthetic
femoral  fracture.  The  latter  healed  after
repeated  osteosynthesis  plus  BMAC  applica-
tion  without  any  consequences.  Other  than
these  2  patients,  no  further  complications
were observed. In particular, no infections, no
excessive new bone formation, no induction of
tumor formation, as well as no morbidity due
to the bone marrow aspiration from the iliac
crest were seen. 
There were no specific complications within
the short follow-up period and a simple intra-
operative use of the system for different forms
of  bone  loss  could  be  demonstrated.  In  the
authors’ opinion, the on-site preparation of the
bone marrow cells within the operating theater
eliminates the specific risk of ex vivo cell pro-
liferation and has a safety advantage in the
use of autologous cell therapy for bone regen-
eration. Additional studies should be complet-
ed to determine efficacy.
Introduction
The  treatment  of  bony  defects  and  bone
healing disorders represents one of the biggest
challenges in orthopedics and trauma surgery.
In order to gain sufficient bone material, previ-
ously  established  operative  procedures
involved  the  drilling  of  neighbouring  sur-
rounding bone, the transplantation of autoge-
nous or allogenic bone and callus distraction,
and  the  additional  use  of  bone  substitution
materials.
1 In contrast to the osteoconductive
bone  substitution  materials  (allogenic  bone,
different  synthetic/natural  biomaterials),
recombinant growth factors from the group of
bone  morphogenic  proteins  (BMPs)  induce
the  formation  of  new  bone
2,  also  in  ectopic
sites. Their possible mechanism of action is
via local activation of mesenchymal precursor
cells. In animal experiments, the direct trans-
plantation  of  mesenchymal  precursor  cells
leads  to  osteoinduction.
3 Clinical  results  of
transplantations of precursor cells in patients
with necrosis of the femoral head, non-unions
or  other  bone  healing  disturbances  have
shown the first promising results.
4-12So far cell-
based  therapies  for  bone  regeneration  have
only propagated to a limited extent due to the
considerable logistical time and effort needed,
and the complicated legal constraints in many
countries with correspondingly high logistical
requirements and exorbitant costs.
In the meantime, however, approved autolo-
gous cellular preparation systems are available
for human use which allow quantitatively rele-
vant purification and concentration of mononu-
clear cells from bone marrow aspirate directly
in the operating theater.
13 The objective of the
present study is to record complications and
evaluate  short-term  clinical  results  in  101
patients  in  whom  intra-operative  autologous
BMAC  with  mesenchymal  and  hematopoietic
precursor cells isolated by means of a density
centrifugation procedure were used.
Materials and Methods
Patients
A total of 101 patients (female/male: 48/53,
mean age: 51 years) with bone healing disor-
ders  or  osteonecrosis  were  surveyed  in  a
prospective  clinical  surveillance  study  with
additive application by BMAC. The indication
for supportive therapy with BMAC was carried
out in 37 cases due to necrosis of the head of
the femur, and in 32 patients because of avascu-
lar osteonecrosis/bone marrow edema of anoth-
er localization. BMAC was also used in 12 cases
of non-unions and 20 times in bone healing dis-
orders of another origin or for bone induction
(arthrodesis of the upper ankle joint, humeral
four-fragment fractures, and others)(Figure 1). 
All patients received information about the
planned operation with all general and typical
risks and complications. In addition, extensive
clarification of and documentation concerning
the  practical  procedure  of  the  intended  cell
therapy was provided, including the novelty of
the  method  of  BMAC,  the  insufficient  long-
term experience, as well as the potential risk
of therapeutic failure, an excess of new bone
formation, the possible activation of existing
infections (e.g. malaria) or cancer. Attention
was also drawn in particular to the so-called
unknown  ‘surgical  risks’.  Patient  consent  to
participate  in  the  clinical  surveillance  study
was obtained. 
In all patients, X-rays of the affected body
region were performed pre-operatively as well
as  post-operatively  in  2  planes.  In  several
cases, MRI studies were also performed. There
were no additional X-rays performed due to the
study.
Bone marrow aspirate concentrate
application
The harvesting of autologous bone marrow
Orthopedic Reviews 2009; volume 1:e32
Correspondence:  Christian  Hendrich,  Ortho-
paedic  Hospital  Schloss  Werneck, Balthasar-
Neumann-Platz 1, 97440 Werneck, Germany. 
E-mail:christian.hendrich@kh-schloss-werneck.de
Key words: bone marrow aspirate concentrate
application.
Received for publication: 25 September 2009
Revision received: 9 December 2009
Accepted for publication: 9 December 2009
This work is licensed under a Creative Commons
Attribution 3.0 License (by-nc 3.0).
©Copyright C. Hendrich et al., 2009
Licensee PAGEPress, Italy
Orthopedic Reviews 2009; 1:e32
doi:10.4081/or.2009.e32[page 100] [Orthopedic Reviews 2009; 1:e32]
was performed under standardized conditions
by Yamshidi vacuum aspiration from the dor-
sal or ventral iliac crest using a stab incision.
Intra-operative  processing  and  concentration
of the mononuclear cells took place under stan-
dardized conditions in the operating theater by
density gradient centrifugation using an auto-
matic,  micro-processor  controlled  centrifuge
system  (SmartPReP  Bone  Marrow  Aspirate
Concentrate System BMAC
TM, Harvest Technol-
ogies GmbH, Munich, Germany) consisting of
a sterile two-chamber centrifuge process kit as
described  previously.
12 The  initial  volume  of
harvested bone marrow was 60 mL or 120 mL
with anticoagulation (heparin/ACD-A solution
8 mL or 16 mL, respectively), according to the
area of application and indication. After cen-
trifugation for 15 min and segregation of the
erythrocyte portion of the cell suspension, the
nucleated cells and plasma were automatically
decanted  into  the  second  chamber  of  the
process kit. After process completion, the plas-
ma  was  removed  leaving  a  predetermined
BMAC volume of 7-10 mL for the surgical appli-
cation which was handed on to the surgeon via
a sterile adapter. 
In case of osteonecrosis, a core decompres-
sion was performed and BMAC was delivered
via a decompression drill channel as an addi-
tive injection (n=72). In 17 cases of osteosyn-
thesis and in 12 cases of other operations due
to disturbed bone healing or for the indication
of new bone formation in the defective osseous
zone, BMAC was applied locally as biomaterial-
cell-composite. 
Subsequently, the bone substitute material
(CopiOs
® Bone Void Filler, Zimmer, Freiburg,
Germany) was used as a bio-absorbable calci-
um phosphate (dibasic) compound with osteo-
conductive properties
14,15 while the BMAC was
mixed with the carrier material immediately
before the implantation.
In the event of a transcutaneous puncture in
femoral head necrosis, a target wire was posi-
tioned through the neck of the femur to the
subchondral necrosis zone via a stab incision.
After image intensifier controls in 2 planes,
the  transcutaneous,  fan-shaped  counter-bore
in the sense of a core decompression was per-
formed  with  a  long  canulated  4.5  mm  drill.
Subsequently, the drill was pulled back a few
millimeters creating an osseous canal, which
was checked by introducing a Kirschner’s wire
in order to remove any drill dust immediately
before the BMAC suspension was injected via
the drill using a short redon tube. 
The  post-operative  treatment  consisted  of
adequate medication for pain treatment, phys-
iotherapeutic measures with relief of the lower
extremities for four weeks as well as the par-
tial loading with 20 kg for a further four weeks.
In the case of avascular necrosis, post-opera-
tive MRI controls were carried out after four
and eight weeks (Figure 2). 
Follow-up 
Demographic  parameters  and  diagnosis
were  determined  pre-operatively.  Post-opera-
tive complications were recorded as part of the
clinical progress examinations and also taken
from the patients’ files. Patients were ques-
tioned about the incidence of complications,
further surgical interventions and their sub-
jective satisfaction. In particular, pain or com-
plications at the removal site and subjective
problems  from  the  bone  marrow  aspiration
were registered.
Results
The mean post-examination period for all
patients was 14 months (2-24 months). With
regard to subjective satisfaction, 84 patients
were satisfied or very satisfied with the result
of the operation, 7 patients reported moderate
satisfaction  and  one  patient,  for  whom  the
indication of a total hip replacement was made
during the further course of recovery, evaluat-
ed  the  procedure  as  non-satisfactory.
Article
Figure 2. A 53-year old patient with necrosis of the head of the femur with accompany-
ing large bone marrow edema on the right side. Transcutaneous core decompression and
BMAC transplantation. MRI controls after four and eight weeks. In addition to the clear-
ly distinguishable drill channels, an almost complete normalization of the bone marrow
signal can be seen.
Figure 1. Indications in
101  autologous  mes-
enchymal  stem  cell
transplantations. AVN:
avascular necrosis.
Other bone defects/
insufficient bone healing
Non-union
AVN, femored head
Before 
surgery
4 weeks 
after core 
decompression/
BMAC 
application
8 weeks 
after core 
decompression/
BMAC 
application
AVN, other 
than hipIndependent of the total level of satisfaction,
pain reduction was achieved in all patients. 
Further surgery was needed in 2 patients.
These were the only complications which were
noted during this follow-up period. In particu-
lar, no complications in the form of infections,
excessive  new  bone  formation  or  renewed
increase of complaints were noted. Also, there
were no cases of complications or morbidity
with respect to the bone marrow removal site.
Subjectively, the bone marrow aspiration was
not  considered  negatively  by  any  of  the
patients.
Case 1
A male patient (age 36 years) had suffered a
lateral fracture of the neck of the femur two
years previously while playing football which
had been treated using a dynamic hip screw. A
radiologically  confirmed  necrosis  of  the
femoral head with incipient subchondral frac-
ture  according  to  Association  Research
Circulation  Osseous  (ARCO)  stage  III  was
shown. The patient was offered a trial of BMAC
cell  therapy  after  clarification  about  the
unfavourable  mid-term  prognosis  of  a  joint-
preserving therapy by means of core decom-
pression. While the post-operative period was
uneventful, within five months a further col-
lapse  of  the  femoral  head  occurred  which
required total joint replacement (Figure 3).
Case 2
A female patient (age 86 years) had suffered
a periprosthetic femur fracture caused by a fall
after total hip replacement. The fracture had
been treated by means of a less invasive stabi-
lization system (LISS) plate. After two months,
plate  breakage  occurred  due  to  inadequate
bone healing and was treated by re-osteosyn-
thesis  with  bone  substitute  material  and
BMAC. After a further three months, an incipi-
ent axial deviation could be seen in the area
around the operation site despite distinct new
bone  formation.  An  additional  femur  plate
osteosynthesis from the anterior was inserted
with additional bone substitute material and
BMAC.  Histological  examination  of  tissue
material from the former transplantation dis-
played a distinct formation of new woven bone.
The fracture then healed uneventfully after a
further three  months (Figure 4).
Discussion 
The  objective  of  our  investigation  was  to
show whether the intra-operative concentra-
tion of mesenchymal progenitor cells is to be
considered a low risk procedure for patients.
Specific  complications  from  the  method  of
stem cell transplantation did not occur in any
of the 101 patients. In particular, no complica-
tions were observed concerning excessive new
bone formation, infections, tumor induction or
morbidity at the removal site on the iliac crest.
However,  further  surgery  was  needed  in  2
patients  within the follow-up period. In one
case,  there  was  a  further  fracture  of  the
femoral  head  after  stem  cell  transplantation
following post-traumatic necrosis of the head
of the femur in Stage III which led to implanta-
tion of a total hip replacement. Here the thera-
py carried out was considered to be a rescue
attempt and the patient was informed accord-
ingly.  During  plate  osteosynthesis  in  a
periprosthetic fracture of an 86-year old female
patient, secondary loss of correction occurred
with loosening of the LISS plate proximal to
the  fracture.  This  is  a  typical  complication,
particularly of elderly patients,
16 even without
additive  application  of  BMAC.  Marked  bone
formation in the area of transplanted BMACs
was confirmed histologically at re-osteosynthe-
sis.  After  additional  internal  fixation  and
BMAC  application,  the  fracture  healed
uneventfully within three months. In all other
patients, the clinical situation improved with-
out further surgery. 
The  treatment  of  bone  healing  disorders
with purified bone marrow is not a new thera-
py. Attempts at direct bone marrow inoculation
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Figure 4. An 86-year old female patient with periprosthetic fracture after total hip revi-
sion surgery showed a failure of LISS osteosynthesis. Re-osteosynthesis was combined
with  application  of  bone  substitute  material  (CopiOs®)  augmented  by  autologous
BMAC. Despite good new bone formation, increasing axial deviation was noted after two
months. Additional internal fixation by plate osteosynthesis from the anterior combined
with a second CopiOs/BMAC transplantation was performed. Here, some tissue from the
initial transplantation site was taken for histology. The patient showed a solid fusion of
the fracture after a further three months post-operatively. The histological analysis of the
transplantation site showed a significant new formation of woven bone (polarization
optics, magnification x 200).
Figure  3.  A  36-
year  old  patient
with  necrosis  of
the  head  of  the
femur after DHS.
BMAC  trans-
plantation  with
incipient  sub-
chondral  frac-
ture.  During  the
further course of
treatment,  there
was  collapse  of
the femoral head
followed  by  a
total  joint
replacement.[page 102] [Orthopedic Reviews 2009; 1:e32]
fail due to the volumes necessary for success-
ful therapy. For this reason, the concentration
of mononuclear cells with the help of density
gradient  centrifugation  was  developed.  With
this procedure a mixed population of different
cells is produced including mesenchymal pre-
cursor cells: colony forming units-fibroblastic
(CFU-F) and hematogenic stem cells (CD34
+-
cells).
10,11 In  a  prospective  study  in  patients
with avascular necrosis of the femoral head
treated with this method, it could be shown
that no total joint had to be implanted after an
average of seven years in 94 of 116 patients.
Local  or  systemic  side-effects  were  not
observed.
4 Also, in 53 of 60 patients with non-
infected atrophic non-unions, healing of the
fracture could be achieved by the injection of
precursor cells from autologous bone marrow
which  had  been  purified  in  the  laboratory.
Based on the analysis of the failures, it was
shown that the number of injected progenitor
cells plays a critical role. As a rule of thumb, it
has  been  suggested  that  1  ml  bone  marrow
contains sufficient numbers of cells to form 1
ccm of bone.
7,9 
In a controlled study with 13 patients (18
hips) with necrosis of the femoral head a clear
difference could be determined between the
active treatment and the control group. In addi-
tion to a significant reduction of pain, disease
progression was also positively influenced by
the treatment with stem cell concentrate.
17-19 
Ultimately, cell therapy by density gradient
centrifugation  outside  the  operating  theater
according to the current European legislation
requires  a  good  manufacturing  practice
(GMP)-certified hematologic laboratory with a
manufacturing  permission  for  medicines
[Advanced  Therapy  Medicinal  Products
(ATMPs) and associated national amendments
for tissue engineering products and cell thera-
peutics].
20 This  is  currently  clearly  hindered
not  least by the legal and bureaucratic obsta-
cles, in particular for the therapy of non-vital
threatening  diseases,  a  category  which
includes bone healing disorders.
21
Therefore, so far there are only individual
data  on  the  efficiency  of  ex  vivo expanded
mesenchymal progenitor cells with the objec-
tive  of  a  clinical  application  to  the  muscu-
loskeletal  system.
22 The  first  studies  have
shown the feasibility in principle on a small
patient  cohort  with  non-union  (n=13)  and
necrosis of the femoral head (n=3; n=6).
23-25 In
addition to the increased laboratory effort, it is,
however, not yet clear to what extent cell prop-
agation in the laboratory leads to a change in
the biological properties of the subsequently
transplanted progenitor cells (in vitro ageing,
polyploidization of the genetic material, trans-
differentiation)  and  the  related  risks  for
patient  safety.
26 The  closed  centrifugation
process used in the present study avoids or
minimizes these risks, as has been shown in
the  data  of  other  working  groups.
13,27
Furthermore,  the  described  technique  as  a
minimum  invasive  procedure  reduces  the
amount of bone to be transplanted and thus
contributes to a shorter operating time as well
as to a reduction in the co-morbidity associat-
ed with excessive bone removal.
In a study with osseous substance defects,
bone healing was achieved in connection with
bone substitution material in all 24 patients.
Infections or wound healing disorders did not
occur.
16 Also, in jaw surgery the successful use
of  BMAC  transplantation  in  a  case  of  jaw
pseudoosteoarthritis  has  been  reported.
28 In
addition  to  these  first  positive  results,  the
present study shows that no significant specif-
ic risks and complications are connected with
the intra-operative removal and purification of
progenitor  cells  in  a  relevant  number  of
patients. The weakness of the present study is
that it is not a prospective randomized study
and there was only a relatively short follow-up
period.  Accordingly,  long-term  post-surgical
examinations  and  studies  are  necessary  on
statistically  relevant  patient  numbers.  The
good  results  in  femoral  head  necroses  and
pseudoosteoarthritis  which  were  achieved
with progenitor cells purified in the laboratory
makes this simple procedure  a valuable addi-
tion to the previous therapy options. 
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